We previously reported the preliminary outcome of a phase I study investigating the use of LMP1&2 and EBNA1-specific CTL immunotherapy generated using a novel adenoviral vector, AdE1-LMPpoly, in a cohort of palliative NPC patients with active refractory disease.19 This evidence concerns the gene PDLIM7 and nasopharyngeal carcinoma.